Ocugen Inc represents values of innovation, collaboration, and excellence in the biopharmaceutical industry. The company is dedicated to addressing unmet medical needs and improving patient outcomes through the development and commercialization of novel therapies. Ocugen Inc is committed to prioritizing patients and ensuring the highest standards of quality and safety in their products. With a focus on research and development, the company strives to bring breakthrough treatments to market, aiming to transform the lives of patients worldwide. Ocugen Inc's corporate philosophy centers around a patient-centric approach, ethical conduct, and delivering value to shareholders.

Ocugen Inc is primarily present in the United States, focusing on the development and commercialization of innovative gene therapies. The company's headquarters are located in Malvern, Pennsylvania. Ocugen Inc also has a strong presence in India, where it has a subsidiary called Ocugen India Pvt. Ltd. Through partnerships and collaborations, Ocugen Inc strives to expand its reach globally, with a mission to provide solutions for rare and underserved diseases worldwide.

Ocugen Inc has achieved several significant milestones in its history. The company successfully secured a strategic collaboration with Bharat Biotech to co-develop COVAXIN, a potential COVID-19 vaccine, for the US market. Ocugen also submitted a Emergency Use Authorization (EUA) application to the US FDA for COVAXIN, which marks a major milestone in bringing a potential vaccine to the market. Additionally, Ocugen received orphan drug designation from the FDA for its gene therapy product candidate for the treatment of RHO mutation-associated retinal degenerative disease. These milestones demonstrate Ocugen's dedication to advancing innovative healthcare solutions and its potential for growth in the biopharmaceutical industry.

Ocugen Inc is a pharmaceutical company with a strong focus on developing and commercializing gene therapies to treat blindness diseases. Established in 2013, Ocugen has been dedicated to advancing innovative treatments for various ocular disorders. The company's proprietary modifier gene therapy platform has shown promising results in preclinical and early clinical trials. Ocugen also partners with biopharmaceutical companies to expedite the development and distribution of potential therapies. With a commitment to improving patients' vision and quality of life, Ocugen Inc continues to make strides in the field of ophthalmology research and development.

The main competitors of Ocugen Inc in the market include companies like Pfizer Inc, Moderna Inc, Johnson & Johnson, and Novavax Inc.

Ocugen Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Ocugen Inc is focused on developing and commercializing transformative therapies for rare and underserved diseases. With a particular emphasis on gene therapies, the company aims to address unmet medical needs and provide effective treatment options for patients worldwide. Ocugen Inc collaborates with strategic partners to develop innovative therapies, leveraging their expertise in gene therapy platforms and advanced formulation techniques. By harnessing the power of genetic engineering and biotechnology, the company strives to bring life-changing solutions to patients suffering from various ophthalmic and other genetic disorders.

Ocugen KGV ir -4,62.

Ocugen KUV ir 114,59.

AlleAktien kvalitātes vērtējums Ocugen ir 3/10.

gaidāmā Ocugen apgrozījums ir 2,57 milj. USD.

gaidāmā Ocugen peļņa ir -63,58 milj. USD.

Ocugen Inc is a biopharmaceutical company based in the USA that focuses on the development and commercialization of innovative therapeutics for eye diseases. Ocugen's business model is based on partnerships with leading companies in the pharmaceutical industry as well as the development of its own products. The company operates in various areas including the development of therapeutics for eye diseases, licensing of technologies, products, and patents, and conducting clinical trials. Ocugen offers a variety of products, such as OCU300 for glaucoma patients and OCU200 for patients with dry eye disease. The company also has other products in the pipeline, such as OCU400 for retinal degeneration and OCU450 for retinal pigment degeneration. Ocugen's business model is focused on the development and commercialization of innovative therapeutics for eye diseases through partnerships and the development of its own products. By continuously evolving and expanding its offerings, Ocugen is well-positioned to meet the increasing demand for effective therapeutics for eye diseases in the future.

Ocugen izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Ocugen vai uzņēmums nedod dividendes.

Ocugen ISIN ir US67577C1053.

Ocugen WKN ir A2PSZH.

Ocugen simbols ir OCGN.

Pēdējo 12 mēnešu laikā Ocugen maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Ocugen plāno maksāt dividendes 0 USD apmērā.

Ocugen pašreizējā dividendu rentabilitāte ir .

Ocugen maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Ocugen pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Ocugen tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Ocugen apmērā 0 USD, kas tika izmaksāta 27.07.2025., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 27.07.2025..

Pēdējās dividendes izmaksa notika 27.07.2025..

Gadā 2024, Ocugen izmaksāja 0 USD dividendes.

Ocugen dividendes tiek izmaksātas USD.